Company:  ATARA BIOTHERAPEUTICS, IN ... (ATRA)
Form Type:  424B5
Filing Date:  1/4/2018 
CIK:  0001604464 
Address:  611 GATEWAY BLVD
SUITE 900
 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  650-278-8930 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$34.59  
Change: 
0.47 (1.38%)  
Trade Time: 
Oct 23  
Market Cap: 
$1.57B
Trade ATRA now with 

© 2018  
Description of Business
Atara Biotherapeutics is a leading T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. The Company's off-the-shelf, or allogeneic, T-cells are bioengineered from donors with healthy immune function and allow for rapid delivery from inventory to patients without a requirement for pretreatment. Atara's T-cell immunotherapies are designed to precisely recognize and eliminate cancerous or diseased cells without affecting normal, healthy cells. Atara's most advanced T-cell immunotherapy in development, tabelecleucel (formerly known as ATA129), is being developed for the treatment of patients with Epstein-Barr virus, or EBV, associated post-transplant lymphoproliferative disorder, or EBV+ PTLD, who have failed rituximab, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma, or NPC.
Register and access this filing in:     
  FORM 424B5
    Dilution
    U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, ...
    Underwriting
    Experts
    TABLE OF CONTENTS
      INCOME STATEMENT
    ABOUT THIS PROSPECTUS
    Use of Proceeds
    RISK FACTORS
    SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    RATIO OF EARNINGS TO FIXED CHARGES
    DESCRIPTION OF CAPITAL STOCK
    Transfer Agent and Registrar
    DESCRIPTION OF DEBT SECURITIES
    DESCRIPTION OF WARRANTS
    PLAN OF DISTRIBUTION
    LEGAL MATTERS
    WHERE YOU CAN FIND MORE INFORMATION